Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resist… Ended

2022-501139-17-01 Aggressive Variant Metastatic Castration Resistant Pros 2023-05-05
A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based the… Ended

2022-500721-32-01 AML and MDS patients failing or being refractory to hyp 2023-05-03
A window-of-opportunity trial with high-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colore… Ended

2022-502524-41-00 pMMR/MSS 2023-05-02
ETOP 22-22 ADEPPT: A study of adagrasib for patients with KRASG12C-mutant non-small cell lung cancer (NSCLC), who are elderly or who are unw… Ended

2023-510463-35-00 Patients with KRASG12C-mutant NSCLC, including patients 2023-04-26
IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre… Ended

2022-502103-30-00 advanced non-squamous non-small cell lung cancer 2023-04-25
Phase 2 study of belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma Ended

2024-516250-22-00 The study will enroll adult participants with RRMM who 2023-04-17
ETOP 18-21 AMAZE-lung: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed w… Ended

2024-512288-29-00 Patients with EGFR-mutant (L858R or del19 only) advance 2023-04-11
International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended

2023-507180-19-00 Cancer 2023-04-05
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Met… Ended

2023-505816-39-00 Untreated Locally Advanced Unresectable or Metastatic R 2023-04-04
Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) pati… Ended

2024-511439-84-00 non-resectable hepatocellular carcinoma (HCC) 2023-03-30
Phase II study of Atezolizumab plus Tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal… Ended

2023-509485-38-00 Squamous cell carcinoma of the anal canal 2023-03-29
A study to assess safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC) Ended

2024-511370-72-00 Primary Sclerosing Cholangitis 2023-03-29
A clinical trial to investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of A… Ended

2023-507052-69-00 Multifocal Motor Neuropathy 2023-03-29
Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limi… Ended

2024-512224-11-00 Histologically confirmed frail Limited Disease Small Ce 2023-03-24
A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended

2022-500953-17-00 Moderately to severely active ulcerative colitis 2023-03-23
A Phase 1b/2 Study of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in Participants with BC and other Advanced Solid Tu… Ended

2023-509504-15-00 HR-positive HER2-negative metastatic/advanced BC 2023-03-20
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol… Ended

2024-513949-37-00 previously untreated aggressive B-cell lymphoma 2023-03-16
A Study of Giredestrant in Patients with Grade 1 Endometrial Cancer Ended

2023-504091-23-00 Grade 1 Endometrial Cancer 2023-03-14
Phase 2 Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Ended

2023-509583-22-00 Neoplasms, Rectal 2023-03-14
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Un… Ended

2023-505211-21-00 Previously untreated locally advanced or metastatic non 2023-03-10
A Phase 2a Study to Evaluate the Safety and Efficacy of MK-5475 in Adults With Pulmonary Hypertension Associated with Chronic Obstructive Pu… Ended

2022-501201-13-00 Pulmonary hypertension associated with chronic obstruct 2023-03-01
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TR… Ended

2023-506082-60-00 Chronic Kidney Disease 2023-02-28
A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin… Ended

2024-518486-10-00 Non-Muscle Invasive Bladder Cancer 2023-02-23
DARIUS : A randomized non-comparative phase II multicentric trial on short term DARolutamide (ODM-201) concomitant to radiation therapy for … Ended

2023-509494-23-00 Adult patients with intermediate unfavorable risk prost 2023-02-20